<DOC>
	<DOC>NCT03048526</DOC>
	<brief_summary>Patients with mild to moderate dry eye disease will be randomized to receive either NovaTears® or Hydrabak® eye drops as control.</brief_summary>
	<brief_title>Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Men and women aged over 18 years History of dry eye disease for at least 3 months before the screening visit Be able and willing to follow instructions, including participation in all study assessments and visits Signed and dated written informed consent Have any clinically significant slitlamp findings at the screening visit that may include trauma, Steven Johnson syndrome, and/or in the opinion of the investigator may interfere with study parameters Participation in a clinical trial in the 4 weeks preceding the before the screening visit Active ocular allergies or ocular allergies that are expected to be active during the study period Pregnancy, planned pregnancy or lactating Known hypersensitivity to any component of the study medication Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>